Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kanghua Out-Licenses Norovirus Vaccine Candidate to HilleVax in $270 Million Deal

publication date: Jan 10, 2024

Chengdu Kanghua Biological Products (Kangh) out-licensed global (ex-China) rights for its norovirus vaccine candidate to Boston’s HilleVax in a $270 million agreement. Norovirus is the leading cause of gastroenteritis (vomiting and diarrhea). HIL-216 includes virus-like particles (VLPs) for six of the most common norovirus genotypes. In 2021, HilleVax, was formed by Japan’s Takeda Pharma to develop another norovirus vaccine candidate, HIL-214 (formerly TAK-214), outside of Japan. Kangh will receive $15 million up front and up to $255.5 million in milestones, plus single-digit tiered royalties. More details....

Stock Symbols: (SHZ: 300841) (NSDQ: HLVX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here